Welcome to our dedicated page for IDEXX Laboratories SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When IDEXX Laboratories rolls out a next-generation Catalyst analyzer or reports another surge in recurring consumables, the details first surface in its SEC filings. Segment revenue for Companion Animal, Water, and Livestock, R&D costs behind diagnostic innovation, and the cadence of software subscriptions—all live inside the company’s 10-K and 10-Q reports. If you have ever searched for “IDEXX Laboratories quarterly earnings report 10-Q filing” or wondered how to spot insider confidence in “IDEXX Laboratories executive stock transactions Form 4,” you know how time-consuming a 300-page document can be.
Stock Titan’s AI-powered summaries turn that complexity into clarity. Our system reads each IDEXX filing the moment it hits EDGAR, delivers real-time alerts on Form 4 insider trades, and explains water-testing margins or software renewals in everyday language. Whether you need a quick glance at an 8-K material event, a deep dive into the annual report—“IDEXX Laboratories annual report 10-K simplified”—or a line-by-line “IDEXX Laboratories proxy statement executive compensation” breakdown, you’ll find it here. Expert analysis highlights which disclosures move the animal-health market and why.
Use cases span the professional spectrum: monitor “IDEXX Laboratories Form 4 insider transactions real-time” before material announcements, compare quarter-over-quarter growth with our “IDEXX Laboratories earnings report filing analysis,” or simply bookmark this page for “IDEXX Laboratories SEC filings explained simply.” Every filing type—10-K, 10-Q, 8-K, S-8, Schedule 13G—is archived with live updates and AI context so you can focus on decisions, not document hunting. Understanding IDEXX Laboratories SEC documents with AI has never been this straightforward.
IDEXX Laboratories entered into Amendment No. 2 to its fourth amended and restated credit agreement, dated November 12, 2025. The amendment adds a three‑year term loan facility and extends the revolving credit facility maturity to five years from the closing date.
The credit arrangement now consists of an unsecured $1.0 billion revolver and an unsecured $250 million term loan, with flexibility to add up to $250 million in incremental revolving commitments and/or term loans. Borrowings may be used for general corporate purposes.
Interest is benchmarked to currencies and tenors selected, with margins tied to the consolidated leverage ratio: for U.S. dollars, base rate or Adjusted Term SOFR/Daily Simple SOFR with margins ranging from 0.0%–1.375%. Comparable benchmarks apply for CAD (PRIMCAN/Term CORRA), EUR (EURIBOR) and AUD (BBSY). Obligations are guaranteed by certain U.S. subsidiaries, with future material U.S. subsidiaries required to guarantee. Covenants include a consolidated leverage ratio and customary negative covenants; events of default are customary, including a change of control.
IDEXX Laboratories (IDXX): Executive Vice President reports option exercises and stock sales. On 11/07/2025, the officer exercised non-qualified stock options to acquire 7,125 shares at $288.78 and 5,405 shares at $505.53. The insider then sold 5,114 shares at a weighted average price of $702.2017, 1,465 shares at $703.7339, 1,468 shares at $704.8659, and 1,378 shares at $705.5448.
Following these transactions, the officer beneficially owned 21,148.9435 shares directly, plus 160 shares held indirectly jointly with spouse. Derivative holdings reported as remaining include 1,604 options. Footnotes note weighted-average sale prices with full breakdowns available upon request and prior vesting schedules for the exercised options.
IDEXX Laboratories (IDXX): Director Joseph L. Hooley reported the acquisition of 39 deferred stock units on 10/30/2025 under the company’s Director Deferred Compensation Plan, coded “A.” The filing lists a reference price of $628.54 per share and states the units were issued in exchange for deferred cash compensation of $24,375.00.
Each deferred stock unit represents a contingent right to receive one share of common stock. The units vest immediately upon grant and are payable as common stock following the director’s resignation from the Board or at other nondiscretionary dates allowed by the plan. Following the transaction, 39 shares are beneficially owned directly.
IDEXX Laboratories reported higher third‑quarter results in its Form 10‑Q for the period ended September 30, 2025. Total revenue rose to $1,105,239 thousand from $975,543 thousand a year ago, driven by the Companion Animal Group, where CAG Diagnostics recurring revenue reached $873,273 thousand. Product revenue was $656,159 thousand and service revenue was $449,080 thousand.
Gross profit increased to $683,354 thousand from $596,038 thousand. Net income grew to $274,610 thousand, with diluted EPS of $3.40 compared with $2.80 last year. By category within CAG, IDEXX VetLab consumables were $387,813 thousand, reference laboratory services $362,725 thousand, and CAG Diagnostics capital instruments $51,479 thousand. Water revenue was $54,297 thousand and LPD revenue was $33,944 thousand.
Year‑to‑date operating cash flow was strong at $826,045 thousand. The company repurchased $979,190 thousand of common stock year‑to‑date and ended with cash and cash equivalents of $208,166 thousand. Borrowings under the Credit Facility totaled $455,000 thousand, and total debt (current and long‑term) was $524,822 thousand as of quarter‑end. Shares outstanding were 79,851,330 on October 29, 2025.
IDEXX Laboratories, Inc. announced quarterly results for the period ended September 30, 2025. The company furnished a press release as Exhibit 99.1 with additional details. The information was provided under Item 2.02 of Form 8‑K and is being furnished, not filed, meaning it is not subject to Section 18 liability and is not incorporated into other filings unless specifically referenced.
IDEXX Laboratories (IDXX) filed a Form 3 showing initial beneficial ownership by a reporting person who is a Director. The filing reports 0 shares of Common Stock beneficially owned (Direct) and no derivative securities listed in Table II. The date of the event requiring the statement is 10/06/2025, and the form was filed by one reporting person. The submission is signed by Karen Peacock on 10/14/2025.
IDEXX Laboratories announced the election of Karen Peacock to its Board of Directors in a press release dated
Idexx Laboratories insider Form 4: Jonathan Jay Mazelsky, identified as President and CEO and a director, reported a disposal of 1,051 shares of Idexx common stock on 08/15/2025. The form shows 1,051 shares disposed and 82,443.3016 shares beneficially owned following the transaction. The filing was signed by Lily J. Lu as Attorney-in-Fact on 09/04/2025.
Martin A. Smith, Executive Vice President of IDEXX Laboratories (IDXX), reported insider transactions dated 09/01/2025. The filing shows an acquisition of 18 shares of IDEXX common stock and a disposition of 5 shares, leaving reported beneficial ownership figures of 1,438.659 and 1,433.659 shares after each transaction respectively. The filing also records 18 restricted stock units (RSUs) tied to those shares; the RSU grant vests in four annual installments beginning September 1, 2022 and represents contingent rights to one share each. The filing discloses that 28.709 shares were purchased earlier under the issuer’s Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025. A price of $647.09 is shown for the disposed shares, noted as the Nasdaq closing price on August 29, 2025. The form is signed by an attorney-in-fact on behalf of Mr. Smith.
FAQ
What is the current stock price of IDEXX Laboratories (IDXX)?
What is the market cap of IDEXX Laboratories (IDXX)?
